Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | ME3 | Q16798 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | FPR1 | P21462 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL549924 | 1.00 | ALDH1A1 (0.45) | ALDH1A1EPHX2ME3ABL1TSHR | |
| SCHEMBL2699537 | 0.90 | DDB1 (0.38) | ALDH1A1KMT2AMAPTKDM4EL3MBTL1 | |
| SCHEMBL2699532 | 0.90 | DDB1 (0.38) | ALDH1A1KMT2AMAPTKDM4EL3MBTL1 | |
| SCHEMBL549439 | 0.89 | MAPT (0.50) | ALDH1A1KMT2AMAPTKDM4EL3MBTL1 | |
| SCHEMBL549440 | 0.89 | MAPT (0.50) | ALDH1A1KMT2AMAPTKDM4EL3MBTL1 | |
| SCHEMBL4570035 | 0.87 | AADAT (0.40) | ALDH1A1KMT2AMAPTKDM4EHTT | |
| SCHEMBL549314 | 0.85 | CRBN (0.46) | ALDH1A1ABL1TSHRKMT2AMAPT | |
| SCHEMBL2700381 | 0.85 | CRBN (0.46) | ALDH1A1ABL1TSHRKMT2AMAPT | |
| SCHEMBL2700378 | 0.85 | CRBN (0.46) | ALDH1A1ABL1TSHRKMT2AMAPT | |
| SCHEMBL549313 | 0.85 | CRBN (0.46) | ALDH1A1ABL1TSHRKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812005-B1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-09-16 | — | — | EP | claimed |
| US-8563570-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | claimed |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | claimed |
| EP-2450351-A1 | Lactam compounds and their use as pharmaceuticals | Incyte Corporation (US) | 2012-05-09 | — | — | EP | claimed |
| US-8110581-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-02-07 | — | — | US | claimed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | claimed |
| EP-1812005-A2 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-08-01 | — | — | EP | claimed |
| US-20060116382-A1 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-01 | — | — | US | claimed |
| WO-2006053024-A2 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-05-18 | — | — | WO | claimed |
| EP-1812005-B1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-1812005-B1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-09-16 | — | — | EP | disclosed |
| US-8563570-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| US-8110581-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110581-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-02-07 | — | — | US | disclosed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | disclosed |
| US-20060116382-A1 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116382-A1 | Lactam compounds and their use as pharmaceuticals | HSD11B1, HSD11B2, HSD17B1 | ALDH1A1 177/4885EPHX2 1615/4885ME3 692/4885 |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | ALDH1A1 177/4885EPHX2 1615/4885ME3 692/4885 |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | ALDH1A1 177/4885EPHX2 1615/4885ME3 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.